# Emergent BioSolutions Inc.: Form 10-K for the period ended Dec 31, 2016

- Company: [Emergent BioSolutions Inc.](/companies/ebs.md) (CIK 1367644)
- Form: 10-K
- Filed: 2017-02-28
- Accepted by EDGAR: Feb 27, 2017, 20:38 ET
- Period: 2016-12-31
- Accession: 0001367644-17-000014
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1367644/000136764417000014/form10-k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1367644/000136764417000014/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-10-01 to 2016-12-31 | $151.7m | us-gaap:SalesRevenueNet |
| Gross profit | 3 months, 2016-10-01 to 2016-12-31 | $50.9m | us-gaap:GrossProfit |
| Research and development | 12 months, 2016-01-01 to 2016-12-31 | $108.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2016-01-01 to 2016-12-31 | $143.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2016-01-01 to 2016-12-31 | $105.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2016-01-01 to 2016-12-31 | $7.6m | us-gaap:InterestExpense |
| Income tax | 12 months, 2016-01-01 to 2016-12-31 | $36.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-10-01 to 2016-12-31 | $37.4m | us-gaap:ProfitLoss |
| Net income | 12 months, 2016-01-01 to 2016-12-31 | $51.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-10-01 to 2016-12-31 | $0.77 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2016-01-01 to 2016-12-31 | $1.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-10-01 to 2016-12-31 | $0.93 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2016-01-01 to 2016-12-31 | $1.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2016-01-01 to 2016-12-31 | 49,335,112 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months, 2016-01-01 to 2016-12-31 | $76.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2016-01-01 to 2016-12-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-12-31 | $271.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $510.2m | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $970.1m | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $105.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-12-31 | $373.9m | us-gaap:Liabilities |
| Long-term debt | at 2016-12-31 | $248.1m | us-gaap:LongTermDebtNoncurrent |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1367644/000136764417000014/form10-k.htm

Filed Feb 28, 2017.
Source: SEC EDGAR, the filing index for accession 0001367644-17-000014. Last ingested by Listed: Nov 4, 2026, 16:51 ET. No prices; not investment advice.
